Literature DB >> 18444249

Optimized multi-stage designs controlling the false discovery or the family-wise error rate.

Sonja Zehetmayer1, Peter Bauer, Martin Posch.   

Abstract

When a large number of hypotheses are investigated, we propose multi-stage designs where in each interim analysis promising hypotheses are screened, which are investigated in further stages. Given a fixed overall number of observations, this allows one to spend more observations for promising hypotheses than with single-stage designs, where the observations are equally distributed among all considered hypotheses. We propose multi-stage procedures controlling either the family-wise error rate (FWER) or the false discovery rate (FDR) and derive asymptotically optimal stopping boundaries and sample size allocations (across stages) to maximize the power of the procedure. Optimized two-stage designs lead to a considerable increase in power compared with the classical single-stage design. Going from two to three stages additionally leads to a distinctive increase in power. Adding a fourth stage leads to a further improvement, which is, however, less pronounced. Surprisingly, we found only small differences in power between optimized integrated designs, where the data of all stages are used in the final test statistics, and optimized pilot designs where only the data from the final stage are used for testing. However, the integrated design controlling the FDR appeared to be more robust against misspecifications in the planning phase. Additionally, we found that with increasing number of stages the drop in power when controlling the FWER instead of the FDR becomes negligible. Our investigations show that the crucial point is not the choice of the error rate or the type of design, but the sequential nature of the trial where non-promising hypotheses are dropped in the early phases of the experiment.

Mesh:

Year:  2008        PMID: 18444249     DOI: 10.1002/sim.3300

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  5 in total

1.  Post hoc power estimation in large-scale multiple testing problems.

Authors:  Sonja Zehetmayer; Martin Posch
Journal:  Bioinformatics       Date:  2010-02-25       Impact factor: 6.937

2.  Effectiveness of strategies to increase the validity of findings from association studies: size vs. replication.

Authors:  Rolf Weitkunat; Etienne Kaelin; Grégory Vuillaume; Gerd Kallischnigg
Journal:  BMC Med Res Methodol       Date:  2010-05-28       Impact factor: 4.615

3.  A simple and flexible graphical approach for adaptive group-sequential clinical trials.

Authors:  Toshifumi Sugitani; Frank Bretz; Willi Maurer
Journal:  J Biopharm Stat       Date:  2014-11-05       Impact factor: 1.051

4.  False discovery rate control in two-stage designs.

Authors:  Sonja Zehetmayer; Martin Posch
Journal:  BMC Bioinformatics       Date:  2012-05-06       Impact factor: 3.169

5.  Controlling type I error rates in multi-arm clinical trials: A case for the false discovery rate.

Authors:  James M S Wason; David S Robertson
Journal:  Pharm Stat       Date:  2020-08-12       Impact factor: 1.894

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.